PF-06425090

PF-06425090 is an investigational bivalent toxoid vaccine developed by Pfizer for the prevention of Clostridium difficile infection (CDI). The vaccine is composed of genetically and chemically detoxified versions of C. difficile toxin A (TcdA) and toxin B (TcdB), which are the primary virulence factors responsible for the symptoms of CDI. It is formulated with aluminum hydroxide as an adjuvant to enhance the immune response. The vaccine was designed to elicit neutralizing antibodies against these toxins to prevent the cytotoxic effects associated with infection. Although it received FDA Fast Track designation in 2014, the Phase 3 CLOVER trial failed to meet its primary endpoint of preventing primary CDI in adults aged 50 years and older, leading to the termination of its development for this indication.

Other names

Clostridium difficile vaccineC. difficile vaccine